CBX7 inhibits YAP/TAZ, down-regulates CTGF (adverse prognostic product of tumor) with PRC2 as a member of PRC1, and reduces the phosphorylation level of c-Jun NH2-terminal kinase (JNK) (Nawaz et al., 2016). Here, CBX7 is linked to neoplasm.